Thank you again for submitting your manuscript to our editorial office. Enclosed below are the reports of the three expert referees that have evaluated it. As indicated in my previous email, the referees acknowledge the structural insights into the Pex4-Pex22 complex as well as their potential mechanistic implications, but at the same time raise a number of caveats that in our view preclude publication of the study in The EMBO Journal, at least in the current form. While I am not going to repeat all the individual points of criticism in detail here, I think it is fair to summarize the main concerns under two main issues: -that is remains unclear on the biochemical level how Pex22 stimulates or 'coactivates' Pex4, or whether it may really act as noncanonical E3 enzyme instead -that it is not clear how the observed in vitro effects of Pex22 on Pex4 would bear out for in vivo ubiquitination of Pex5, especially in light of the likely additional involvement of Pex5 ubiquitin ligases Given the number of (often overlapping) concerns raised in this respect by all three referees, we feel that decisively addressing them will likely require substantial further time and effort (of unclear outcome), which appears to be beyond the scope of the single round of revision we usually ask for. As we only publish a small percentage of the many manuscripts submitted to The EMBO Journal, we can really only invite revision for those few submissions that receive elevated enthusiasm from the referees already upon initial review, and that appear to be sufficiently close to becoming acceptable during a limited revision period. Since this is unfortunately not the case here, I see little choice but to return the paper to you with the message that we cannot consider a revision in this case, and that you may at this point be best advised to seek rapid publication without major changes in a more structural journal. Should you however be prepared to develop the study further in line of the comments and suggestions of our referees, I would in light of the potential interest of this study not exclude the possibility of discussing a single resubmission on this topic at some point in the future; this would however have to be treated as a new submission and only go back to our referees if we thought that the main issues had been largely answered and the key conclusions decisively substantiated, and if the conceptual novelty should still be warranted by then.
Thank you in any case for the opportunity to consider this manuscript. I am sorry we cannot be more positive on this occasion, but we hope nevertheless that you will find our referees' comments helpful.
Yours sincerely, Editor The EMBO Journal _______________________ Referee reports Referee #1 (Remarks to the Author):
This manuscript describes the structure of a complex of Pex4p and the soluble domain of Pex22p. Pex22p enhances the activity of Pex4p in vitro. The structure of the complex shows a novel interaction surface between the Pex4p and Pex22p. Mutation in a critical residue on the E2, Y172A, abrogates interaction with Pex22p and reduces the activity of Pex4p in the presence of Pex22p.
The ability of E2 binding protein to stimulate E2 activity has been reported for Cue1p/Ubc7p. The cytosolic domain of Cue1p promotes the formation of polyubiquitin chain on Ubc7p in the absence of E3 in vitro although the structural basis for Cue1p/Ubc7p interaction is not yet known. This study is interesting and could provide insights into how an E2 binding partner could stimulate E2 activity in the absence of E3. However, this study can benefit from more analysis of the mechanism by which Pex22p stimulates Pex4p activity.
However, it is also not clear whether the structure of Pex4p changes in the presence of Pex22p. This may be difficult in the absence of a structure of the E2 alone. The authors propose that binding of Pex22p could make the E2 more "rigid." Are the authors proposing that rigidity of the E2 is associated with more stable structure or that rigidity is associated with ore favorable conformation for ubiqutin transfer?
One major question is whether Pex22p stimulate the rate of ubiquitin conjugation or the elongation of ubiquitin chain by Pex4p. In Fig 1, the effect of Pex22p appears to be enhancing the formation of polyubiquitin chain. On the other hand, Fig 5 suggests that the rate of reaction may be slower for Y172A mutant. Since Y172A mutation completely abrogates interaction with Pex22p, one would expect Y172A to function similarly in the presence or absence of Pex22p. This is not the case however. Experiments that distinguish between enhanced rate of reaction and polyubiquitin chain elongation will be needed to better answer this question.
Another question is whether Pex22p affects the expression of Pex4p in vivo. It would be important to show the levels of Pex4 and mutants in Fig 7. The ubiquitin status of Pex5p is confusing and would require elaboration. The authors show also discuss the difference between the effects of Ubc4p and Pex22p ubiquitination on Pex5p.
Finally the effect of Pex22p on E2:E3 interaction is not investigated. Although it is interesting that Pex22p could stimulate polyubiquitination of the E2 in the absence of E3, it is not clear whether that is the major function of Pex22p in vivo.
Referee #2 (Remarks to the Author):
In this manuscript, Williams and coworkers determined the crystal structure of the Pex415-183:Pex22S complex from the yeast Saccharomyces cerevisiae. They also demonstrated that Pex22S stimulates Pex4(15-183)'s E2 ubiquitin-conjugating activity in vitro, which helps the formation of additional Ub moieties to make lysine 48 linked Ub chains on Pex415-183. Using in vivo experiments involving Pex4 mutations that fail to interact with Pex22, they conclude that Pex4:Pex22 assembly, but not Pex4 alone, is required for Pex5 ubiquitination in vivo.
The conclusions from the crystal structure and in vitro experiments are clear and justified and represent, in principle, an important advance for the peroxisome biogenesis field. However, while the paper does a fine job on the structure, it could do more on the functional implications of the structure and the conclusions made for the in vivo significance. The authors should be encouraged to revise the MS, as explained below.
It is interesting that in vitro Pex22 appears to stimulate the attachment of multiple Ub (linked via K48) to Pex4. However, in vivo the authors have not focused on whether Pex22 binding allows Pex4 to attach two Ub moieties to the cycling receptor Pex5 as has been shown in vivo by Kragt et al. (2005) . Fig 7 only shows mono-ubiquitinated Pex5.
What the authors show nicely is that the Pex4:Pex22 interaction is needed in vitro for charging the E2, Pex4, efficiently, but this is then extrapolated to state that "Pex22 binding is essential for Pex4 to ubiquitinate its target, the Pex5 import receptor in vivo". How can the authors distinguish whether the inefficiency in ubiquitinating Pex5 in vivo is due to one or more of the following -(a) inefficient charging of Pex4 with Ub, (b) inefficient interaction of Pex4 with the appropriate E3 ligase, which they state is still unknown, (c) instability of Pex4, as suggested by the ITC experiments, or (d) inefficient ubiquitination of the Pex5 target alone? In other words, what step/s is Pex22 co-activating exactly?
The authors appear to have the tools to identify the E3 ligase needed for Pex4-dependent ubiquitination of Pex5, and should do this work.
The conclusions from the in vivo experiments could be more convincing. The major problem is that they did not provide strong data to demonstrate that Pex22 is an E2/co-activator required for Pex5 ubiquitination in vivo. For example, the authors made a mutation of Pex4 (eg. Pex4-Y172A) to detect the effect of the binding site of Pex4 on Pex4's E2 ubiquitin-conjugating activity in vivo, but they did not show any data to demonstrate that Pex22 serves as an E2/co-activator in vivo. To demonstrate that Pex22 is essential for Pex4's E2 ubiquitin-conjugating activity and functions as an E2/co-activator required for Pex5 ubiquitination in vivo, the authors need to add more experimental data, such as - (1) What is the effect of mutations in the Pex4 binding site of Pex22 on Pex22-Pex4 interaction in vivo? To prove this, they need to show co-immunoprecipitation of Pex22 (and its binding site mutations) with Pex4, in addition to the effect on Pex5 ubiquitination in vivo. (3) How does Pex22 affect the Pex5 ubiquitination as an E2/co-activator in vivo? To prove this, they need to do some in vivo ubiquitination assays to show how Pex22 (and its binding sites mutations) affects Pex5 ubiquitination in vivo. This manuscript describes the structure of a complex between Pex4, a ubiquitin E2 enzyme and Pex22, a socalled coactivator and attempts to establish that the complex is the active form of the E2 enzyme. The paper makes the argument that the role of Pex22 is therefore not solely localization to the peroxisome (which was shown before), but also functions to activate the E2.
The paper suffers from a lack of controls as detailed below, but this important point, the dual recruitment and activation function will hopefullly hold up with the proper controls as detailed below and it is a very interesting finding. However, the manuscript does not address the fundamental question whether this should be called a coactivator or an E3 ligase. Clearly Pex22 stimulates intrinsic activity of the E2 and in the usual nomenclature this would be called an E3 enzyme. In this case there are additional RING E3s present in the cellular environment, and I guess that is why the designation 'coactivator' was chosen by the authors.
Ideally it would therefore be very interesting to figure out if these are really working simultaneously, since one could also envisage two step models, where Pex22 is required first and then the ring E3s come in. Although that may be too much for this manuscript, it is important to discuss this possibility. In the light of the role as an alternative type of E3 enzyme, the paper should probably discuss the other E3 variants such as RanBP2 and the viral ligases and their mode of action.
In addition there are a number of important technical issues in this manuscript that need to be addressed -The biochemical analysis should show full gels ( not cut off at 43 kD), show the free ubiquitin and include controls in the absence of E1 and E2 respectively. -The assay descriptions are missing: e.g. buffer conditions, method of stopping reactions, time points in several different assays.
-ITC data should include the titration curve and the fitting to be acceptable for publication. Also ITC can never be used to prove lack of binding, since interaction could be purely entropic and then not be visible either. -The CD data don't add anything to the story. It would be better to remove them or at least move them to the supplemental data.
-Please mention what methods were used to compare the fold to the PDB and give the cutoff that was used to define lack of significance (usually dali/ssm will find some homologs, so z-score cut-off would be appreciated) -Please include the Ubc9/importin complex in the comparisons, since it seems to interact in this region also We have tried to obtain structural data on Pex4p alone, unfortunately without success. Our CD data suggest that no significant change in the overall secondary structure of Pex4p Figure S5B) . The complex, on the other hand retains much of its secondary structure at higher temperatures, indicating a more rigid arrangement (Supplementary Figure   S5F To provide further insight into Pex22p's mode of action, we have performed additional in vitro experiments, following the transfer of ubiquitin from E1 to Pex4p, as well as the rate of transfer of ubiquitin from Pex4p to substrate, both in the presence and absence of Pex22p.
Our new data demonstrate that Pex22p binding does not enhance charging of Pex4p by the E1 (Figure 2A ) but that it is involved in the conjugation of ubiquitin to a substrate ( Figure 2B ).
As we do not observe ubiquitin chain formation with Pex4p alone, even after 120 min incubation periods ( Figure 6B) Figure   7C . To avoid confusion, we have referred to the two different forms of Pex5p ubiquitination as either Ubc4p-or Pex4p-dependent ubiquitination, depending on the E2 involved.
Additionally, we have discussed this point in the text and have included molecular weight markers with the western blots, allowing direct comparison with the published data.
What the authors show nicely is that the Pex4:Pex22 interaction is needed in vitro for charging the E2, Pex4, efficiently, but this is then extrapolated to state that "Pex22 binding is essential for Pex4 to ubiquitinate its target, the Pex5 import receptor in vivo". How can the authors distinguish whether the inefficiency in ubiquitinating Pex5 in vivo is due to one or more of the following -(a) inefficient charging of Pex4 with Ub, (b) inefficient interaction of Pex4 with the appropriate E3 ligase, which they state is still unknown, (c) instability of Pex4, as suggested by the ITC experiments or (d) inefficient ubiquitination of the Pex5 target alone? In other words, what step/s is Pex22 co-activating exactly?
(a) In vitro analysis of the transfer of ubiquitin from E1 to the active site cysteine in Pex4p
indicates that charging of Pex4p with ubiquitin does not require Pex22p (Figure 2A ). Figure 7B ). 
The authors appear to have the tools to identify the E3 ligase needed for Pex4-dependent ubiquitination of Pex5, and should do this work.
Please see the response to Referee #1's last comment. While this is of course a very interesting and relevant issue and is indeed a future direction for our research, we feel that identifying the E3 ligase functioning with Pex4p goes beyond the scope of the current manuscript. We have added the suggested reference.
The conclusions from the in vivo experiments

On page 7, line 11. What are the roles of the conserved Asp151, Ala165, Gly168 and Ile169 in the function of Pex4 and its interaction with Pex22?
Due to the fact that these residues are conserved, we believe they are involved in complex formation, but that their role is more peripheral than that of Tyr 172. During the course of this study, we have made a number of mutants in the interface, with several of them exhibiting a lower level of Pex22p binding. However, due to the strong nature of the interaction between the two proteins, this reduction in binding does not alter the affect Pex22p exerts on Pex4p's activity, neither in vitro nor in vivo. Consequently, we have only presented our data on the Y172A mutant.
In Fig.5, we can still see some Ub2-Pex4 at T120. It looks like the ubiquitination of Pex4Y172A+Pex22S may just be delayed compared to wild type Pex4+Pex22S. Have longer incubations been attempted?
Please see the response to Referee #1's second comment.
In Fig. 7A, how do the authors know that ubiquitination of Pex5 is Ubc4 dependent as stated?
We and others have reported that Pex5p can be modified by, depending on the circumstances, Pex4p and Ubc4p (Platta et al., 2004, PMID: 15283676; Kragt et al., 2005, PMID: 15632140; Williams et al., 2007, PMID: 17550898) . Ubc4p-dependent ubiquitination of Pex5p occurs when the recycling process is disturbed; an effect often observed when late acting PEX genes (including PEX4 and PEX22) are knocked out. The pattern of Pex5p ubiquitination seen with our mutants ( Figure 7A , second and fourth lanes) corresponds to that seen when the PEX4 gene is knocked out (Figure 7A , last lane) and matches the pattern of Ubc4p-dependent ubiquitination reported in the literature.
Please explain residue average B factors (page 6) for general readers.
We have added a description explaining residue average B factors in the Results section. Figure 2) showing samples of the in vitro ubiquitination reaction presented in Figure 1A . A reaction containing Pex22 S alone (control in the absence of E2) is shown in Figure 1B (last lane). Since that all the reactions presented in Figure 1 demonstrate the requirement of ATP for ubiquitin conjugation, we felt that controls lacking the E1 would not add to the interpretation of the data.
Comments to Referee #3
-The assay descriptions are missing: e.g. buffer conditions, method of stopping reactions, time points in several different assays.
We have expanded our description of the in vitro ubiquitination assays in the Materials and
Methods section.
-ITC data should include the titration curve and the fitting to be acceptable for publication. Also ITC can never be used to prove lack of binding, since interaction could be purely entropic and then not be visible either.
As requested, we have added the titration curves and fitting for the ITC data (Supplementary Figure 1) . Additionally, we have performed native gel electrophoresis analysis of the Y172A form of Pex4p ( Figure 6A ) and have confirmed its inability to bind Pex22 S in vitro.
-The CD data don't add anything to the story. It would be better to remove them or at least move them to the supplemental data.
As suggested, we have moved the CD data to the Supplementary Information.
-Please mention what methods were used to compare the fold to the PDB and give the cutoff that was used to define lack of significance (usually dali/ssm will find some homologs, so zscore cut-off would be appreciated)
To aid interpretation, we have added a table with the top 10 unique hits as provided by PDBeFOLD (Supplementary Table S2 ), complete with Z-, Q-, and P-scores.
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-Please include the Ubc9/importin complex in the comparisons, since it seems to interact in this region also
We have added a comment relating this structure to our own in the Discussion.
In summary, we have been able to greatly improve our manuscript in accordance with the suggestions of the reviewers and we hope that the changes are sufficient to make the manuscript acceptable for publication in The EMBO Journal. Thank you for submitting your revised manuscript for our consideration. It has now been seen once more by two of the original referees, whose comments are copied below. While referee 1 retains some reservations regarding the in vivo functions of Pex4-Pex22, we feel that in light of the overall improvement of the study, and of the unclear situation regarding Pex5 in vivo ubiquitination and responsible E3 enzymes, these concerns should not further prohibit publication of the study at the current stage. There are some minor points suggested by referee 3 that I would kindly ask you to incorporate in a final round of minor revision; and ideally, showing an additional shorter exposure of the blots in Figure 2 in the supplement, may help to address one of referee 1's lingering concerns.
From an editorial point of view, I was wondering whether somewhat more explicit title could be chosen to appropriately attract the interest of the relevant readership. Minimally, it would help to replace 'E2' in the title with 'ubiquitin-conjugating enzyme'; but I could also imagine a more detailed alternative such as: 'Insights into ubiquitin-conjugating enzyme/coactivator interaction from the structure of the Pex4p-Pex22p complex' (which may be slightly longer than the normally allowed 100 characters but that shouldn't be a problem)
Following these final modifications, we shall be happy to swiftly proceed with the formal acceptance and production of the paper! With best regards,
Editor
The EMBO Journal _____ REFEREE REPORTS:
Referee #1 (Remarks to the Author):
In vitro, Pex22 appears to promote ubiquitin transfer from Pex4, although quantification of the results in Fig 2 is not possible due to overexposure of the unmodified E2 band.
In the absence of expression levels of Pex4, it is difficult to understand the effect of Pex22 in vivo. As the authors have pointed out, the effect of Y172A mutation may still allow transient association sufficient to stimulate E2 activity. On the other hand, expression of Y172A did not rescue effect in vivo. The easiest way to reconcile these differences is that Pex4 levels are affected by Pex22. For example, Cue1 has been shown to stabilize Ubc7 when bound to the E2. The authors could check this by expressing Pex4 with a stronger promoter.
Data on the ubiquitination of Pex5 in vivo remain weak. In the absence of E3 information, it is difficult to understand the roles of Pex22 in vivo.
Referee #3 (Remarks to the Author):
The manuscript has much improved from the previous version, the data are convincing and welldiscussed. This paper provides a very interesting novel mechanism of promoting ubiquitin conjugation. Future work that includes E3 ligases will be eagerly awaited.
two minor points: It would be very nice if the authors could find a different way of describing the binding site on the E2 in stead of 'underside' binding (page 12), since this refers only to their way of orienting the E2 in the figure.
In terms of the analysis of the lack of similar structures, the more extensive explanation of the procedure in the text is welcome, table S2 can be dispensed with, since these are not significant. We have added a shorter exposure of the blots in Figure 2 (Supplementary Figure S2B and C), to aid interpretation of the results. We have indeed expressed Pex4p under the control of a strong promoter and we do not see differences in protein levels, comparing the wild type and Y172A mutant form of Pex4p, employing both soluble and membrane-anchored versions of Pex4p ( Figure 7B ). These results suggest that Pex4p levels are not influenced by the ability of the protein to bind Pex22p and that consequently, the phenotype of the Y172A mutant derives from a loss of Pex22p co-activation, rather than lower protein levels.
Data on the ubiquitination of Pex5 in vivo remain weak. In the absence of E3 information, it is difficult to understand the roles of Pex22 in vivo.
Our in vivo results indicate the crucial contribution Pex22p binding plays in Pex4p's function. However, we appreciate that without data on the E3 ligase, the complete story concerning the role of Pex22p in Pex5p ubiquitination is not yet available and have commented on this in the Discussion. Addressing the E3 ligase link is indeed a future direction for our research.
Comments to Referee #3
We are very pleased by the positive and supportive comments of Reviewer #3. As requested, we have changed our description of the Pex22p binding site. We now refer to this region as the " 3-4" binding site.
In terms of the analysis of the lack of similar structures, the more extensive explanation of the
